Fig 2: iASPP and METTL3 expression in cervical cancer tissues. Representative immunohistochemical images of iASPP negative in adjacent non-tumor cervical tissues (ANCT) (A) and positive in tumor tissues (B), METTL3 negative in ANCT (C) and positive in tumor tissues (D).

Fig 3: Aberrant m6A modification involved in colistin-induced renal injury. (A) Effect of colistin on m6A contents of total RNAs in mTRECs. (B) mRNA levels of m6A modification-associated genes and immunoblotting of METTL3 after colistin treatment. (C) Effect of METTL3 overexpression on m6A contents of total RNAs. Values that are significantly different from the values for the control group are indicated by asterisks as follows: ∗∗p < 0.01. Values that are significantly different from the values for the colistin group are indicated as follows: ##p < 0.01.

Fig 4: METTL3-dependent m6A methylation regulates the processing of mmu-miR-873-5p by DGCR8. (A) Co-IP of the METTL3-interacting protein DGCR8. mREECs were crosslinked before the immunoprecipitation. IgG antibody was used as control. (B) MiR-126 and pri-miR126 were quantified by qPCR in all groups. (C) IP of DGCR8-associated RNA from control or METTL3-overexpressing cells followed by qPCR to detect pri-mmu-miR-873-5p binding toDGCR8. Immunoprecipitation of m6A modified RNA in control or METTL3-overexpressing cells followed by qPCR to assess the pri-mmu-miR-873-5p m6A modification levels. (D) Bioinformatics analysis of predicted interactions of mmu-miR-873-5p with its binding sites in Keap1. Luciferase activity was measured by dual-luciferase reporter assay. Luciferase activity was normalized to Renilla luciferase activity. (E) Western blot and qPCR analysis of Keap1, Nrf2, and HO-1 expression. The values that are significantly different from the values relative to control group are indicated by asterisks as follows: ∗∗p < 0.01. Values that are significantly different from the values of colistin-treated group are indicated as follows: ##p < 0.01.

Fig 5: Kaplan-Meier survival curves of iASPP and METTL3 expression in cervical cancer. Cervical cancer patients with high iASPP expression had shorter 5-year recurrence-free survival (RFS) (A, p= 0.002), distant metastasis-free survival (DMFS) (B, p=0.001), progression free survival (PFS) (C, p<0.001) and overall survival (OS) (D, p=0.037) than those with low expression. Patients with high METTL3 expression had worse 5-year RFS (E, p= 0.007), DMFS (F, p=0.016), PFS (G, p<0.001) and OS (H, p=0.042) than those with low expression